My practice is currently full, but you are welcome to enquire about joining my waiting list. Online booking is for existing clients only.

An adult resting with headphones and a blanket while a therapist sits attentively nearby, with her hands resting in her lap.
IFS · Preparation · Journey support · Integration

Psychedelic-assisted therapy

Space for your hopes, your fears and every part of your experience. I support preparation, journeys in countries and settings where this work is legal, and integration, including after a difficult or unsettling journey.

The support I offer

Preparation, support in legal settings, and integration after a journey.

I bring IFS and my relational approach to preparation, journey support and integration. We make room for what you hope for, what worries you, and the support your whole system needs. Work during a psychedelic journey takes place only in countries and settings where it is legally permitted, within the requirements of that setting.

You can also come to me after an experience that left you frightened, overwhelmed, confused or feeling that you were not adequately prepared or supported. You do not need to be planning another journey.

Preparation: listening to your whole system

Preparation is more than arranging the day. Through IFS, we get to know the parts of you that are curious or hopeful, and those that feel cautious, frightened or opposed. We seek permission from your internal system, taking protective concerns seriously rather than trying to persuade them to step aside.

We listen to what each part hopes for and fears: “What if I lose control?”, “What if something comes up that I cannot manage?”, “What if nothing happens?” There is time to ask questions, explore possible experiences and be honest about what nobody can predict. We return to concerns that need more attention, without expecting you to have no fear.

We also discuss boundaries, communication, sensory needs, who will be present, how support will be offered and what happens afterwards. Readiness can include deciding to wait, change the plan or not go ahead.

Support before, during and after

BeforePreparation

Build trust inside and around you

Listen to hopes and protective fears, seek internal permission, explore your questions and agree the support and boundaries you need.

DuringIn a legal, supported setting

Attentive support while experience unfolds

A session may include music, eyeshades, quiet inward attention and conversation when you want it. Supporters stay available, help you orient if you feel overwhelmed and respect agreed consent and boundaries. If parts become noticeable and you want support with them, IFS can help us meet them with curiosity and compassion. We follow what emerges, with room for quiet, reassurance or conversation, rather than directing the journey.

AfterIntegration

Find what helps in everyday life

Integration gives us space to explore what happened and how it is affecting you now. We can listen to parts, make room for feelings, images and questions, and care for anything that feels unresolved. Together, we consider how what emerged might belong in everyday life. There is no need to settle on a meaning or rush into changes.

The details vary with the medicine and setting. Medical suitability, medicine provision and monitoring are handled by the appropriately authorised professionals involved.

Set and setting: the context matters

Set is what you bring into a journey: expectations, emotions, hopes, fears and what is happening in your life. Setting is the environment around you: the space, sensory conditions, people, relationships and sense of safety.

Trust, clear boundaries and feeling able to communicate can affect how supported you feel. For neurodivergent people, lighting, sound, transitions and predictability may need particular attention. Preparation gives these needs a place in the plan.

What might a journey feel like?

Experiences differ. There is no one right journey.

You may notice changes in emotion, perception, body sensations, time or your sense of self. Some moments feel connected or spacious; others may be confusing, painful or frightening. Experiences can change direction, and they do not always resemble what you expected.

In a supported setting, you can turn towards your experience or ask for contact and reassurance. If something feels overwhelming, the focus is on helping you feel supported and responding to what you need. A journey does not need to be intense to matter. We pay attention to how it affects you and the support you need.

Afterwards you may feel love, spaciousness, connection or relief. You may also feel tired, clear, unsettled or full of questions, and several feelings can be present together. We make space to understand your experience at a pace that feels safe.

In my own journeys, what emerged has been what I needed, even when it was not what I wanted at the time. I have also seen this in my professional work. That has not made the difficult moments easier, but recognising it has helped me meet them with more trust. Your own experience and what it means to you have room here too.

Different medicines, different experiences

MedicinePossible experienceThings to understand
PsilocybinA classic psychedelic. Perception, emotions, time and the sense of self can change markedly.Studied for depression and some substance use disorders, including alcohol and tobacco use. Anxiety, nausea and headache can occur; experiences and outcomes vary.
MDMAAn empathogen, often associated with greater connection and emotional openness. Difficult feelings can still arise.Studied alongside therapy for PTSD, with preliminary alcohol-use research. Physical effects include increased pulse and blood pressure. Its effects and evidence differ from classic psychedelics.
KetamineA dissociative anaesthetic. Some people describe dreamlike experiences or distance from their body or surroundings.Used by specialist depression services, sometimes off-label. Also being studied with psychological therapy for alcohol use disorder. Dizziness, nausea and blood-pressure changes can occur; benefits may fade and further treatment may be needed.

These are broad descriptions, not predictions or a recommendation for you. Suitability depends on your health, circumstances, the medicine and the support available. Read the addiction research below.

Psilocybin: 2026 clinical trial ↗ · MDMA: 2025 discussion of evidence limitations ↗ · Ketamine: NHS benefits and risks ↗

Why draw on MAPS?

A framework for connected care before, during and after a journey.

MAPS is the Multidisciplinary Association for Psychedelic Studies. Its MDMA-assisted therapy manual describes how preparation, support during a medicine session and integration fit together. It gives practical attention to trust, consent and staying with the person’s experience rather than directing it.

I draw on that framework to think about continuity of care: knowing someone before a journey, supporting what arises and helping afterwards. The manual was developed for MDMA and PTSD; it is not a universal protocol for every medicine or person. Read the MAPS therapy manual ↗.

Why bring IFS into the work?

Listen to hopes and protective concerns without pushing either aside.

IFS offers a way to listen to your internal system throughout the work. A hopeful part may long for relief; another may fear vulnerability or losing control. We get to know both and work towards a plan your system can agree to, rather than letting one part overrule another.

During and after an experience, we can notice which parts need reassurance, what has shifted and what still feels unresolved. IFS is the therapeutic approach I bring. Early research describes ways it may support integration, including self-compassion and making sense of internal experience. There are encouraging findings, alongside questions that need larger comparative studies. Read the evidence and its limits below.

Integration without pressure

Make room for what happened, rather than what you think should have happened.

Integration is a place to explore what happened and how it is affecting you now. We can stay with feelings, body responses, images or questions, using conversation, drawing, imagery or sandtray when helpful. You remain the person who decides what the experience means to you.

If a journey was frightening or left you feeling unlike yourself, we begin with what helps you feel steadier. We can listen to parts that still feel alarmed, revisit moments that need support and consider what would help you feel more connected in everyday life.

You may feel you were not sufficiently prepared, or that your needs and boundaries were missed. We can explore that carefully. IFS preparation aims to build trust with protective parts, seek their permission and reduce the risk of overwhelm or protective backlash. I take that seriously rather than hoping parts will cope on the day. Preparation can help create a more supported journey, although we cannot predict everything that will arise. If an experience was difficult, we can explore what preparation or support was missing without blaming you. Explore the IFS clinical skills manual.

An adult exploring an experience through creative materials in an attentive conversation with a therapist.
Making sense of your experience, with support and room for your own meaning.

What the research can and cannot tell us

Depression and preparation

A 2026 UK trial with 60 people found greater improvement in treatment-resistant depression with psilocybin and psychological support than with placebo and support. It was a feasibility study with a short follow-up, and most participants could tell which treatment they received. Larger confirmatory studies are needed. Read Rucker and colleagues, 2026 ↗.

A 2026 review of 12 controlled trials found that more preparatory therapy was associated with greater improvement in depressive symptoms. This is an association across studies, not proof that insufficient preparation causes a difficult journey. Integration quantity was not significantly associated with symptom improvement in that analysis; this does not measure all the ways someone may need support afterwards. Most studies had a high risk of bias. Read Florineth and colleagues, 2026 ↗.

A 2025 review of 42 psilocybin studies found that many reported side effects were temporary, while serious events were uncommon in screened, supported clinical settings. Blinding limitations affected all included studies, and these findings cannot simply be transferred to every setting or person. Read Bukovsky and colleagues, 2025 ↗.

IFS alongside psychedelic therapy

A 2026 qualitative study by Sarrassat and Hill interviewed four people who used IFS for psychedelic integration. They described support in understanding parts, finding language for their experiences and developing self-compassion. The sample was small and selected, and people with positive views of IFS may have been more likely to volunteer. It offers insight into their experiences, without comparing IFS against another therapy. Read the 2026 IFS integration study.

A 2024 pilot report described reduced distress among 29 people attending a programme combining ketamine, IFS group therapy and creative and nature-based integration. There was no control group, and the different elements were offered together, so we cannot tell how much change came from IFS itself. Read Swoap’s pilot report.

A critical appraisal by Earleywine and colleagues, published online in 2024, highlighted limited outcome evidence and the need for careful research and monitoring of benefits and harms. This is a critique of the evidence, not a trial showing that IFS fails. The studies above are encouraging, but do not tell us whether IFS works better than another approach alongside the same medicine. Read the critical appraisal.

Addiction and patterns that feel hard to change

Research into addiction is developing, particularly for psilocybin with psychological support. A 2022 alcohol-use trial found fewer heavy-drinking days, while a 2025 trial after alcohol withdrawal did not find improved abstinence or drinking outcomes. A 2026 smoking-cessation pilot found higher abstinence with psilocybin and CBT than nicotine patches and CBT, but was small and unblinded.

Ketamine is also being studied for alcohol use disorder. A 2022 phase 2 trial found more abstinent days with ketamine than placebo, but no significant difference in relapse rates. A larger UK trial is investigating ketamine with psychological therapy.

MDMA research for alcohol use disorder remains preliminary. A 2025 analysis of a 14-person open-label study reported encouraging changes in craving and drinking risk. Without a control group, it cannot establish how much change came from MDMA or the accompanying therapy.

These findings cannot be assumed to apply to every addiction, compulsive pattern or medicine. In our therapeutic work, we can also be curious about what a pattern does for you, the parts seeking relief and the parts concerned about its effects, without shame or blame.

Care shaped around you

We talk openly about your health, medication, previous experiences and the support available, with medical questions explored by the appropriate clinician. Your identity, sensory needs, consent and boundaries belong in that conversation.

If an experience has left you struggling, we can consider what kind of support you need now, including working alongside other professionals. If you need immediate help, urgent support information is here.

Ask about this support

You are welcome to ask about preparation, support in a legal setting, or integration after a past journey. A few lines is enough; you can leave the more personal details for a conversation. Contact Shema.

Watch and explore

A question is enough to begin.

You are welcome to ask whether this support might be right for you. My practice is currently full; enquiries about the waiting list are welcome.

Fees and practical details · Common questions